BOXED O
WARNING O
: O
Do O
Not O
Substitute O
KADCYLA O
for O
or O
with O
Trastuzumab O
WARNING O
: O
HEPATOTOXICITY O
, O
CARDIAC O
TOXICITY O
, O
EMBRYO-FETAL O
TOXICITY O
* O
Hepatotoxicity B-NonOSE_AE
: O
Serious O
hepatotoxicity B-OSE_Labeled_AE
has O
been O
reported O
, O
including O
liver B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
and O
death B-NonOSE_AE
in O
patients O
treated O
with O
KADCYLA O
. O

Monitor O
serum O
transaminases O
and O
bilirubin O
prior O
to O
initiation O
of O
KADCYLA O
treatment O
and O
prior O
to O
each O
KADCYLA O
dose O
. O

Reduce O
dose O
or O
discontinue O
KADCYLA O
as O
appropriate O
in O
cases O
of O
increased B-NonOSE_AE
serum I-NonOSE_AE
transaminases I-NonOSE_AE
or O
total O
bilirubin O
. O

( O
2.2 O
, O
5.1 O
) O
* O
Cardiac B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
: O
KADCYLA O
administration O
may O
lead O
to O
reductions B-OSE_Labeled_AE
in I-OSE_Labeled_AE
left I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
ejection I-OSE_Labeled_AE
fraction I-OSE_Labeled_AE
( I-OSE_Labeled_AE
LVEF I-OSE_Labeled_AE
) O
. O

Evaluate O
left O
ventricular O
function O
in O
all O
patients O
prior O
to O
and O
during O
treatment O
with O
KADCYLA O
. O

Withhold O
treatment O
for O
clinically O
significant O
decrease B-NonOSE_AE
in I-NonOSE_AE
left I-NonOSE_AE
ventricular I-NonOSE_AE
function I-NonOSE_AE
. O

( O
2.2 O
, O
5.2 O
) O
* O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
: O
Exposure O
to O
KADCYLA O
can O
result O
in O
embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
death I-OSE_Labeled_AE
or O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
. O

Advise O
patients O
of O
these O
risks O
and O
the O
need O
for O
effective O
contraception O
. O

( O
5.3 O
, O
8.1 O
, O
8.6 O
) O
EXCERPT O
: O
WARNING O
: O
HEPATOTOXICITY O
, O
CARDIAC O
TOXICITY O
, O
EMBRYO-FETAL O
TOXICITY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
* O
Do O
not O
substitute O
KADCYLA O
for O
or O
with O
trastuzumab O
. O

( O
2.1 O
) O
* O
Hepatotoxicity O
, O
liver O
failure O
and O
death O
have O
occurred O
in O
KADCYLA-treated O
patients O
. O

Monitor O
hepatic O
function O
prior O
to O
initiation O
and O
prior O
to O
each O
dose O
. O

Institute O
dose O
modifications O
or O
permanently O
discontinue O
as O
appropriate O
. O

( O
2.2 O
, O
5.1 O
) O
* O
KADCYLA O
may O
lead O
to O
reductions O
in O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
. O

Assess O
LVEF O
prior O
to O
initiation O
. O

Monitor O
and O
withhold O
dosing O
or O
discontinue O
as O
appropriate O
. O

( O
2.2 O
, O
5.2 O
) O
* O
Can O
cause O
fetal O
harm O
. O

Advise O
women O
of O
potential O
risk O
to O
the O
fetus O
. O

( O
5.3 O
, O
8.1 O
, O
8.6 O
) O

